Lantid Capsule (Enteric Coated) 30 mg

Lantid Capsule (Enteric Coated), manufactured by Opsonin Pharma Ltd, is a proton pump inhibitor containing 30 mg Lansoprazole. This enteric-coated capsule effectively treats acid-related disorders at an affordable price of ৳5.02 per unit. The pack size (3×6 capsules) costs ৳90.36, making it accessible for long-term therapeutic needs.

Clinically proven for duodenal/gastric ulcers and GERD, Lantid inhibits gastric acid secretion by blocking H+/K+ ATPase enzymes. Its enteric coating ensures drug release in the intestine, enhancing efficacy. The medication shows 94% bioavailability when taken 30 minutes before meals, as recommended in prescribing guidelines.

Dosing varies by condition:

• 15-30 mg daily for acid reflux
• 30 mg for 4-8 weeks for ulcer healing
• Up to 120 mg/day divided doses for Zollinger-Ellison syndrome

Patients should swallow capsules whole without crushing to maintain coating integrity.

While generally well-tolerated, 3-8% users report diarrhea or headaches. Long-term use may affect vitamin B12 absorption. Pregnant women should use cautiously after risk-benefit analysis. Store below 25°C in original packaging to preserve stability of this heat-sensitive formulation.

Duodenal ulcer: 30 mg daily before breakfast for 4 weeks; maintenance 15 mg. Zollinger-Ellison syndrome: Start with 60 mg daily, up to 120 mg in divided doses. Gastric ulcer: 30 mg for 8 weeks. Take on empty stomach 30 mins before morning meal. Treatment duration varies from 2-8 weeks based on condition.

Severe or irreversible adverse effects: The possible induction of carcinoid tumors by profound acid suppression, and a rise in serum gastrin may occur. There is a rise in serum gastrin levels in the first 3 months of treatment, which are then maintained though at a lower level than those found in pernicious anaemia. Long term treatment with a proton pump inhibitor in patients with Helicobacter pylori infection may accelerate the development of atrophic gastritis.

Symptomatic adverse effect: Dose dependent diarrhoea occurs with an incidence of about 4% at 30 mg per day, rising to 8% at 60 mg per day. Headache occurs in 2-3% of treated patients

Pregnancy Category B: Use only if clearly needed. Breastfeeding safety unconfirmed; avoid. Consult physician during pregnancy/lactation.

Rule out gastric malignancy before treatment. Monitor liver function tests in hepatic impairment. Check calcium/magnesium levels during long-term therapy. No dose adjustment needed for elderly.

Pediatrics (<13 years): Not recommended. Elderly: Safe without dose adjustment. Hepatic impairment: Dose reduction may be needed. Renal impairment: No specific modifications required.